W STRATEGIES, LLC for ASTRAZENECA PHARMACEUTICALS LP
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Education on the importance of maintaining the competitive elements of the Part D prescription drug program and to oppose efforts to impose mandatory government rebates in that program and proposed changes to cost sharing for low income seniors. H.R.5122: To prohibit further action on the proposed rule regarding testing of Medicare part B prescription drug models. March 2016 CMS proposed rule implementing a new Part B drug payment model.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Health Issues HCR
H.R. 34: 21st Century Cures Act conference report. Education about the value of innovative new medicines.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DARREN WILLCOX | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.